Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant Endostatin With Vinorelbine and Cisplatin (NP) Plus Maintenance Therapy With Recombinant Endostatin for Advanced Non-small Cell Lung Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study

Next Previous
Trial Profile

Recombinant Endostatin With Vinorelbine and Cisplatin (NP) Plus Maintenance Therapy With Recombinant Endostatin for Advanced Non-small Cell Lung Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Apr 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Endostatin (Primary) ; Cisplatin; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Jiangsu Wuzhong Pharmaceutical Group

Most Recent Events

  • 12 Apr 2017 Status changed from recruiting to completed.
  • 25 Jan 2017 Planned number of patients changed from 540 to 560.
  • 24 Jan 2017 Planned End Date changed from 31 Aug 2014 to 31 Jan 2017.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top